

Recognition of Transmembrane Protein 39A as a Tumor-Specific Marker in Brain Tumor

Park, J., Lee, H., Tran, Q., Mun, K., Kim, D., Hong, Y., ... Kim, S-H. (2017). Recognition of Transmembrane Protein 39A as a Tumor-Specific Marker in Brain Tumor. *Toxicological research*, 33(1), 63-69. DOI: 10.5487/TR.2017.33.1.063

Published in:
Toxicological research

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2017 Korean Society of Toxicology.

This is an open access Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/3.0/>), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.



Recognition of Transmembrane Protein 39A as a Tumor-Specific Marker in Brain Tumor

Jisoo Park¹, Hyunji Lee¹, Quangdon Tran¹, Kisun Mun¹, Dohoon Kim¹, Youngeun Hong¹,
So Hee Kwon², Derek Brazil³, Jongsun Park¹ and Seon-Hwan Kim⁴

¹Department of Pharmacology and Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon, Korea

²College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Korea

³Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom

⁴Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Korea

(Received November 28, 2016; Revised November 30, 2016; Accepted December 2, 2016)

Transmembrane protein 39A (TMEM39A) belongs to the TMEM39 family. TMEM39A gene is a susceptibility locus for multiple sclerosis. In addition, TMEM39A seems to be implicated in systemic lupus erythematosus. However, any possible involvement of TMEM39A in cancer remains largely unknown. In the present report, we provide evidence that TMEM39A may play a role in brain tumors. Western blotting using an anti-TMEM39A antibody indicated that TMEM39A was overexpressed in glioblastoma cell lines, including U87-MG and U251-MG. Deep-sequencing transcriptomic profiling of U87-MG and U251-MG cells revealed that TMEM39A transcripts were upregulated in such cells compared with those of the cerebral cortex. Confocal microscopic analysis of U251-MG cells stained with anti-TMEM39A antibody showed that TMEM39A was located in dot-like structures lying close to the nucleus. TMEM39A probably located to mitochondria or to endosomes. Immunohistochemical analysis of glioma tissue specimens indicated that TMEM39A was markedly upregulated in such samples. Bioinformatic analysis of the Rembrandt knowledge base also supported upregulation of TMEM39A mRNA levels in glioma patients. Together, the results afford strong evidence that TMEM39A is upregulated in glioma cell lines and glioma tissue specimens. Therefore, TMEM39A may serve as a novel diagnostic marker of, and a therapeutic target for, gliomas and other cancers.

Key words: TMEM39a, Multiple sclerosis, Systemic lupus erythematosus, Glioma

INTRODUCTION

Glioblastoma multiform (GBM) is the most aggressive form of glioma that arises from astrocytes (1). Approximately 15% of all primary brain tumors are GBMs, which may arise de novo or from low-grade astrocytomas. Genetic

abnormalities are common in GBM patients (2). GBM is malignant, and patients typically die within 1 year of diagnosis (3). GBMs are characterized by the presence of a solid mass of extremely circuitous large-diameter vessels with abnormally thickened basement membranes (4). Functionally, the tumor vasculature is unusual. Vessel permeability is increased, triggering vasogenic edema and hemorrhage (5). As the vessels of the vasculature are highly disorganized, the efficacies of radio- and chemotherapy may be compromised by the abnormal blood flow (6). Recent preclinical and clinical studies have discovered new molecular GBM targets, which may afford opportunities to improve anti-angiogenic strategies (7).

Presently, the drug most often used to target vascular endothelial growth factor (VEGF) is bevacizumab (BEV), a recombinant humanized monoclonal antibody against VEGF-A (8). However, the initially reported beneficial effects of BEV may be (at least in part) attributed to imaging limitations caused by reduced neoangiogenesis and vascular per-

Correspondence to: Seon-Hwan Kim, Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon 35015, Korea
E-mail: neons@cnu.ac.kr

Jongsun Park, Department of Pharmacology and Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Korea
E-mail: insulin@cnu.ac.kr

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

meability. These lead to an apparent (but controversial) decrease in the contrast-enhanced tumor volume (9). Recent prospective phase III trials (using avastin and radiation therapy) sought to validate the efficacy of temozolomide (TMZ)-based radio-chemotherapy, combined with BEV, in GBM patients (10). The “Avastin in GBM” (AVAglio) study showed that progression-free survival (PFS) was significantly prolonged (by 4.4 months) upon BEV co-treatment. In the “Radiation Therapy Oncology Group (RTOG) 0825” trial, no significant benefits were evident in terms of either PFS or overall survival. However, PFS benefits did not translate into improvements in overall survival (11). Therefore, it is necessary to find novel therapeutic targets in GBM patients, since TMZ and anti-VEGF drugs are not adequately efficacious.

Transmembrane protein 39A (TMEM39A) belongs to the TMEM39 family, consisting of TMEM39A and TMEM39B. The two TMEM39 isoforms are produced via alternative splicing (12). Transmembrane proteins extend from one side of the plasma membrane to the other. Many transmembrane proteins control the transport of materials across biological membranes (13). The TMEM39A-encoding gene may be a susceptibility locus for multiple sclerosis (14,15). Furthermore, TMEM39A is associated with systemic lupus erythematosus (16-18). However, no study has yet investigated any possible role for TMEM39A in cancer. Therefore, we sought a putative role for TMEM39A in GBM. Novel therapeutic markers for this brain cancer are needed urgently. Here, we provide clear evidence that TMEM39A is upregulated in GBM cell lines and GBM tissues from patients. This affords novel insight into the role played by TMEM39A in GBM. TMEM39A may be a useful new therapeutic target for brain cancer.

MATERIALS AND METHODS

Antibodies and reagents. Anti-TMEM39A antibody and Anti-Actin antibodies were purchased from Sigma-Aldrich (St. Louis, MO, USA). Horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG secondary antibodies were purchased from Komabiotech (Seoul, Korea).

Patient samples. The study was approved by the Hospital Institutional Review Board (approval number CNUH 2013-11-006) according to the Declaration of Helsinki at Chungnam National University Hospital (Daejeon, Korea), and written informed consent was obtained from each patient by research team before surgery. Normal brain tissue samples were obtained from cadavers alternatively, from autopsy of surrounding normal brain of glioblastoma patient who underwent surgery.

Cell culture. The glioblastoma cells (U87-MG, U251-MG, U343-MG and U373-MG) and non-glioblastoma cell (HEK-293A) were maintained in medium (RPMI) supplemented with 10% FBS, 25 mM HEPES (Thermo Scientific),

1% Antibiotics-Antimycotics (Life Technologies, CA, USA).

Immunoblot analysis. The western blot analysis was performed as the described previously (19-21). Briefly, cells were placed on ice and extracted with lysis buffer containing 50 mM Tris-HCl, pH 7.5, 1% v/v Nonidet P-40, 120 mM NaCl, 25 mM sodium fluoride, 40 mM β -glycerol phosphate, 0.1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamide, and 2 mM microcystin-LR. Lysates were centrifuged for 15 min at 12,000 g. The cell extracts were resolved by 10–15% SDS-PAGE, and transferred to Immobilon-P membranes (Millipore, MA, USA). The filters were blocked for 1 hr in 1 X tri-buffered saline buffer (TBS- 140 mM NaCl, 2.7 mM KCl, 250 mM Tris- HCl, pH 7.4), containing 5% skimmed milk and 0.2% Tween-20, followed by an overnight incubation with the anti-TMEM39A and anti-Actin antibodies diluted 1000-fold at 4°C. The secondary antibody was horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Komabiotech, Seoul, Korea), diluted 5000-fold in the blocking buffer. The detection of protein expression was visualized by enhanced chemiluminescence, according to the manufacturer’s instructions (Thermo Fisher Scientific, CA, USA).

Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Total RNA was extracted from frozen tissue samples or from cells using the PureHelix RNA Extraction Solution (Nanohelix, Seoul, Korea). The cDNA was synthesized from total RNA with the SuperScript III First-Strand Synthesis System for qRT-PCR (Invitrogen, Grand Island, NY, USA). The qRT-PCR measurement of individual cDNAs was performed using SYBR green dye to measure duplex DNA formation with the StepOne Plus real-time PCR system (Invitrogen) and normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RNA. The following primers were used in the qRT-PCR (F: Forward, R: Reverse); Human TMEM39A: F-5'-CCCACCTATCACAGCCTTAATC/R-5'-AAAGAGCA-ACCAACAGGT AGAT; human GAPDH : F-5'-TCGACAGTCAGCCGCATCTTCTTT/R-5'-TACGACCA AAT-CCGTTGACTCCGA.

RNA sequencing and RNA-Seq data analysis. Total RNA of U87-MG, U251-MG and normal brain was extracted using Trizol reagent (Invitrogen) following the manufacturer’s procedures. The total RNA quantity and purity were analysis of Bioanalyzer 2100 and RNA 6000 Nano Lab-Chip Kit (Agilent, Santa Clara, CA, USA). Roughly 10 μ g of total RNA was subjected to isolate Poly (A) mRNA with poly-T oligo attached magnetic beads (Invitrogen). Following purification, the mRNA is fragmented into small pieces using divalent cations under raised temperature. Then the cleaved RNA fragments were reverse-transcribed to create

the final cDNA library in accordance with the protocol for the mRNA-Seq sample preparation kit (Illumina, CA, USA). The average insert size for the paired-end libraries was 300 bp (\pm 50 bp). Next we performed the paired-end sequencing on an Illumina Hiseq 2000 system at Macrogen (Seoul, Korea) following the vendor's recommended protocol. For each sample, sequenced reads were aligned to the UCSC human reference genome (22) using the Tophat package (23), which initially removes a portion of the reads based on quality information accompanying each read and then maps the reads to the reference genome. FPKM (fragments per kilobase of exon per million fragments mapped) were calculated to compare the expression level of TMEM39A mRNA variants in each sample.

Confocal imaging analysis and indirect immunofluorescence. U251-MG cells were grown on glass coverslips until they were 50~70% confluent. After 24 hrs, the cells were fixed in 4% paraformaldehyde at room temperature for 10 min and permeabilized in 0.2% Triton X100 for 5 min at room temperature. Then cells were incubated in blocking buffer containing 5% bovine serum albumin (Sigma-Aldrich) in 1 X TBS for 1 hr at 37°C. The rabbit polyclonal anti-TMEM39A was diluted 200-fold for primary antibody and incubated for overnight. The secondary antibody, FITC-conjugated anti-rabbit antibody (BD Biosciences, NJ, USA) was used. After appropriate rinsing, cover slips were mounted with Vectashield (Vector Laboratories, CA, USA) and visualized using a Zeiss confocal microscope.

Immunohistochemistry. The analysis of Immunohistochemistry was performed as the described previously (24,25). A human cancer tissue array slide with paraffin sections was purchased from Bio Max (US Biomax Inc., MD, USA). Histostain-Plus kits (Zymed Laboratories Inc., CA, USA) were used in accordance with the manufacturer's instructions for the immunohistochemistry of tissue array. Briefly, paraffin sections were deparaffinized with xylene and rehydrated in a graded series of ethanol. The slide was submerged in peroxidase quenching solution for 10 min. After it was washed twice with PBS for 5 min, it was added with 2 drops of Reagent A for blocking and incubated for 30 min. Following two washes with PBS, the primary antibody, anti-TMEM39A antibody, was applied at 4°C for overnight. Then biotinylated secondary antibody, Reagent B, was added after rinsing with PBS. It was incubated at room temperature for 1 hr. It was rinsed with PBS and dropped with enzyme conjugated Reagent C. After it was washed with PBS, DAB chromogen, and a mixture of Reagent D1, D2, and D3, it was dropped, and signals were observed with a fluorescence microscope (Zeiss, Oberkochen, Germany). Then the reaction was stopped with distilled water, and pictures were taken with a microscope.

Bioinformatics data set. Glioma data sets and corresponding clinical data were downloaded from the publicly available databases (446 cases from the Repository of Molecular Brain Neoplasia Data (REMBRANDT; <http://www.betastasis.com/glioma/rembrandt/>). Normal; n = 21, GBM; n = 214, oligodendroglioma; n = 66, Astrocytomas; n = 145.

Statistical analysis. Data are expressed as the mean \pm S.D. from at least three separate experiments performed triplicate. The differences between groups were analyzed using a Student's *t* test and $p < 0.05$ (*) was considered significant, and $p < 0.01$ (**) was highly significant compared with corresponding control values. Comparison of TMEM39A expression in various gliomas was carried out by one-way ANOVA with Dunn's post-test (one variable). Statistical analyses were carried out using SPSS software ver. 13.0 (SPSS Inc., NY, USA). For the analysis of Kaplan-Meier survival curve, *p* values were obtained from log-rank test, while hazard ratio (HR) and 95% confidence interval (CI) were determined by univariate Cox regression model.

RESULTS

Upregulation of TMEM39A expression in glioblastoma cell lines. To explore a putative role for TMEM39A in brain cancer, we performed Western blotting using an anti-TMEM39A antibody. As shown in Fig. 1A, TMEM39A expression was markedly enhanced in U343-MG and U373-MG GBM cells compared with other cell type non-GBM cells, HEK-293A cells. Quantitative real-time PCR (qRT-PCR) of glioblastoma cell lines also showed that the levels of mRNA encoding TMEM39A were elevated in U343-MG and U373-MG cells (Fig. 1B).

TMEM39A transcription is enhanced in U87-MG cells and U251-MG cells. Based on the above observations, TMEM39A mRNA levels were measured by RNA sequencing of glioblastoma cell lines. Total RNA were isolated from two cell lines (U87-MG and U251-MG), which showed the low expression of TMEM39A in Fig. 1A and 1B. Also, we isolated total RNA from normal brain cells. The numbers of "fragments per kilobase of exon per million fragments mapped" (FPKM) were calculated to compare the expression levels of TMEM39A mRNA among the various samples. As shown in Fig. 2, the FPKMs were markedly higher in U87-MG cells (17.08) and U251-MG cells (11.12) than in cerebral cortex cells (1.87), indicating that TMEM39A is transcriptionally upregulated in GBM cells.

Subcellular localization of TMEM39A in U251-MG cells. We used immunocytochemistry to determine the subcellular location of TMEM39A in U251-MG cells. Interestingly TMEM39A was found located in dot-like structures lying




Fig. 1. TMEM39A expression in glioblastoma (GBM) cell lines. (A) Lysates were prepared from four established GBM cell lines (U87-MG, U251-MG, U373-MG, and U343-MG) and one established non-GBM cell lines (HEK-293A). These samples were subjected to Western blotting using anti-TMEM39A and anti-actin antibodies. The results are representative of those of three independent experiments (top panel). Relative densities were obtained by densitometry. Relative differences in TMEM39A expression levels (and the associated statistics) were calculated by normalizing all densitometric values to that of actin (in each lane) and setting the values from HEK-293A cells to 1 (bottom panel). Results are presented as the means \pm SDs of data from three independent experiments. (B) Total RNA extracted from each GBM cell line was analyzed by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using human TMEM39A-specific primers, as described in Materials and Methods. The results are presented as means \pm SDs of data from three independent experiments. * $p < 0.05$, ** $p < 0.01$.




Fig. 2. Relative differences in TMEM39A transcript levels in GBM cells. Total RNAs were isolated from two GBM cell lines (U87-MG and U251-MG) and normal brain tissue. These samples were analyzed by standard RNA deep-sequencing (RNA-seq), as described in Materials and Methods. RNA-seq read densities of TMEM39A transcripts were plotted against relative RNA-seq read coverages (counts). "Fragments per kilobase of exon per million fragments mapped" (FPKM) were calculated to compare the expression levels of TMEM39A mRNA variants among various sample.

close to the nucleus, likely mitochondria and endosomes (Fig. 3). This suggested that the membrane-bound form of TMEM39A was functional in GBM cells.

TMEM39A is expressed in GBM tissue. To determine if the above observations (Fig. 1 and 2) were clinically rele-

vant, we subjected a human cancer tissue array to immunohistochemical analysis. As shown in Fig. 4A, the tumor tissues were stained with an anti-TMEM39A antibody to a greater extent than were the surrounding normal tissues. In addition, total cell lysates from normal and cancerous tissues derived from two GBM patients during surgery were




Fig. 3. Subcellular localization of TMEM39A in U251-MG cells. (A) U251-MG cells were grown on glass coverslips, fixed, and permeabilized with 0.2% (v/v) Triton X-100. After immunostaining with anti-TMEM39A antibody, the cover slips were mounted on Vectashield and examined using a Zeiss confocal microscope. Scale bars: 10 µm.

subjected to Western blotting using an anti-TMEM39A antibody. As expected, GBM tissues expressed TMEM39A more prominently than did the surrounding normal tissues, indicating that TMEM39A expression is upregulated in GBM patients.

Differential TMEM39A mRNA expression and validation of the prognostic value of this observation in the REMBRANDT cohort. Building upon the above observations (Fig. 1-3), we assessed TMEM39A expression levels,

and the prognostic significance of any differences, in gliomas from patients of the REMBRANDT cohort (<http://www.betastasis.com/glioma/rembrandt/>). Consistent with the above results (derived using a tissue microarray, Western blotting, and RNA sequencing), TMEM39A expression was markedly increased in various gliomas (GBMs, n = 214; oligodendroglioma, n = 66; and astrocytomas, n = 145) compared with normal control tissues (n = 21; one way ANOVA P-value < 0.0001; Fig. 5A). Moreover, high-level TMEM39A mRNA expression (in 167 patients), compared with low-level expression (in 31 patients), was significantly associated with poor survival (log-rank P value = 0.012; HR = 2.17, 95% confidence interval [CI] 0.80-2.89; Fig. 5B), suggesting that the TMEM39A expression level is correlated with the clinical prognosis of glioma patients.

DISCUSSION

GBM is the most aggressive type of brain tumor. Prognosis is poor even when multiple therapies are applied. Molecular targeting may be important when developing efficient GBM treatment strategies. Genetic abnormalities are common in GBM patients (2). Therefore, prognostic biomarkers and potential molecular targets must be identified immediately if the disease is to be overcome.

In the present study, we showed that TMEM39A is a novel GBM prognostic marker. TMEM39A is upregulated in GBM cell lines and patient tissues. Genome-wide associ-




Fig. 4. TMEM39A expression levels in human brain tumors. (A) Human glioma tissue arrays were immunohistochemically analyzed in terms of TMEM39A staining. Representative images from samples from two patients are shown. Scale bars: 100 µm. (B) Total cell lysates from normal and GBM tissues (tumors no. 1 and 2) from two patients were analyzed in terms of TMEM39A expression (top panel). Tumor-associated normal tissue served as a control (Tumor Asso.). Relative densities were calculated by densitometry. Relative differences in TMEM39A expression levels were determined by normalizing all densitometric values to those of actin (in each lane) and setting the control values to 1 (bottom panel). The results are presented as means ± SDs of data from three independent experiments. *p < 0.05, **p < 0.01.




Fig. 5. Differential expression of TMEM39A mRNA in glioma specimens from the REMBRANDT cohort. (A) TMEM39A mRNA levels were measured in various normal ($n=21$) and glioma (GBMs, $n=214$; oligodendrogliomas, $n=66$; and astrocytomas, $n=145$) tissues. The median values for each group are indicated by lines and numbers. (B) The Kaplan-Meier curve compares the level of TMEM39A expression with overall survival. P values were obtained using the log-rank test, and hazard ratios (HRs) with 95% confidence intervals (CIs) were determined using the aid of a univariate Cox's regression model.

ation studies (GWASs) recently indicated that TMEM39A is involved in multiple sclerosis (14,15). A GWAS also revealed the involvement of TMEM39A in systemic lupus erythematosus (SLE), a chronic heterogeneous autoimmune disorder characterized by loss of tolerance to self-antigens and dysregulation of interferon synthesis (16-18,26). However, TMEM39A has not yet been implicated in any other disease. Therefore, we investigated whether TMEM39A is involved in the development of brain tumors including GBM. Interestingly, TMEM39A was highly expressed in GBM cell lines, including U343-MG and U373-MG cells (Fig. 1A). qRT-PCR using a TMEM39A-specific primer revealed that these cells express more TMEM39A mRNA (Fig. 1B) than do non-GBM cells, HEK-293A cells. In addition, RNA deep-sequencing of U87-MG and U251-MG cells showed that the FPKMs of TMEM39A mRNA were higher in these cells than in normal brain cells (Fig. 2). Many transmembrane proteins function as gateways or "loading docks", permitting or forbidding the transport of specific substances across biological membranes. Both entry into the cell and exit from the cell (for example of waste byproducts) are thus regulated. Depending on the shapes of the molecules to be transported, "freight-handling" transmembrane proteins may fold or bend the molecules in specific ways (27). We therefore identified the subcellular location of TMEM39A in U251-MG cells. As expected, the protein was present in dot-like structures (probably mitochondria and endosomes, Fig. 3) lying close to the nucleus, suggesting that membrane-binding of TMEM39A is important when the protein plays a role in GBM.

To further evaluate the role played by TMEM39A in GBM progression, we used a tissue microarray and performed Western blotting of patient tissue samples. As shown in Fig. 4A, TMEM39A was upregulated in GBM tissues. This was confirmed by Western blotting of total cell lysates from normal and cancerous tissues sampled during surgery on two

GBM patients (Fig. 4B). We also found that TMEM39A was highly expressed in all gliomas (including GBMs) of patients of the REMBRANDT cohort (Fig. 5A). Furthermore, high-level TMEM39A mRNA expression was correlated with poor overall survival (Fig. 5B), clearly indicating that TMEM39A expression is associated with the clinical prognosis of glioma. Together, the data indicate that TMEM39A is associated with glioma progression, and this molecule may serve as a novel prognostic biomarker of GBM.

ACKNOWLEDGMENTS

This work was financially supported by a research fund from Chungnam National University in 2014 (grant to S.H. Kim) and by National Research Foundation of Korea (NRF) grants from the Korean Government (MEST) (NRF-2012M3A9B6055302, NRF-2014R1A1A3050752, NRF-2015R1A2A2A01003597, NRF-2015R1D1A3A01015694).

REFERENCES

1. Friedmann-Morvinski, D., Bushong, E.A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M.H. and Verma, I.M. (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. *Science*, **338**, 1080-1084.
2. Arif, S.H., Pandith, A.A., Bhat, A.R., Ramzan, A.U., Malik, N.K., Chibber, S.S., Wani, A.A., Tabasum, R. and Kirmani, A. (2015) EGFR and PTEN gene mutation status in glioblastoma patients and their prognostic impact on patient's survival. *J. Carcinog. Mutagen.*, **6**, 218.
3. Virk, S.M., Gibson, R.M., Quinones-Mateu, M.E. and Barnholtz-Sloan, J.S. (2015) Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. *PLoS ONE*, **10**, e0124178.
4. Wesseling, P., Ruiters, D.J. and Burger, P.C. (1997) Angiogenesis in brain tumors; pathobiological and clinical aspects. *J Neurooncol.*, **32**, 253-265.
5. Jain, R.K., di Tomaso, E., Duda, D.G., Loeffler, J.S.,

- Sorensen, A.G. and Batchelor, T.T. (2007) Angiogenesis in brain tumours. *Nat. Rev. Neurosci.*, **8**, 610-622.
6. Das, S. and Marsden, P.A. (2013) Angiogenesis in glioblastoma. *N. Engl. J. Med.*, **369**, 1561-1563.
 7. Carmeliet, P. and Jain, R.K. (2011) Molecular mechanisms and clinical applications of angiogenesis. *Nature*, **473**, 298-307.
 8. Norden, A.D., Drappatz, J. and Wen, P.Y. (2008) Novel anti-angiogenic therapies for malignant gliomas. *Lancet Neurol.*, **7**, 1152-1160.
 9. Chinot, O.L., Macdonald, D.R., Abrey, L.E., Zahlmann, G., Kerloeguen, Y. and Cloughesy, T.F. (2013) Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. *Curr. Neurol. Neurosci. Rep.*, **13**, 347.
 10. Chinot, O.L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A.F., Hoang-Xuan, K., Kavan, P., Cernea, D., Brandes, A.A., Hilton, M., Abrey, L. and Cloughesy, T. (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N. Engl. J. Med.*, **370**, 709-722.
 11. Gilbert, M.R., Dignam, J.J., Armstrong, T.S., Wefel, J.S., Blumenthal, D.T., Vogelbaum, M.A., Colman, H., Chakravarti, A., Pugh, S., Won, M., Jeraj, R., Brown, P.D., Jaeckle, K.A., Schiff, D., Stieber, V.W., Brachman, D.G., Werner-Wasik, M., Tremont-Lukats, I.W., Sulman, E.P., Aldape, K.D., Curran, W.J., Jr. and Mehta, M.P. (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N. Engl. J. Med.*, **370**, 699-708.
 12. Hao, Y., Colak, R., Teyra, J., orbi-Verge, C., Ignatchenko, A., Hahne, H., Wilhelm, M., Kuster, B., Braun, P., Kaida, D., Kisslinger, T. and Kim, P.M. (2015) Semi-supervised learning predicts approximately one third of the alternative splicing isoforms as functional proteins. *Cell Rep.*, **12**, 183-189.
 13. Moon, C.P. and Fleming, K.G. (2011) Side-chain hydrophobicity scale derived from transmembrane protein folding into lipid bilayers. *Proc. Natl. Acad. Sci. U.S.A.*, **108**, 10174-10177.
 14. International Multiple Sclerosis Genetics Consortium (IMSGC) (2010) Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. *Hum. Mol. Genet.*, **19**, 953-962.
 15. Varadé, J., Comabella, M., Ortiz, M.A., Arroyo, R., Fernández, O., Pinto-Medel, M.J., Fedetz, M., Izquierdo, G., Lucas, M., Gómez, C.L., Rabasa, A.C., Alcina, A., Matesanz, F., Alloza, I., Antigué, A., García-Barcina, M., Otaegui, D., Olascoaga, J., Saiz, A., Blanco, Y., Montalbán, X., Vandebroek, K. and Urcelay, E. (2012) Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. *Mult. Scler.*, **18**, 959-965.
 16. You, Y., Zhai, Z.F., Chen, F.R., Chen, W. and Hao, F. (2015) Autoimmune risk loci of IL12RB2, IKZF1, XKR6, TMEM39A and CSK in Chinese patients with systemic lupus erythematosus. *Tissue Antigens*, **85**, 200-203.
 17. Sheng, Y.J., Xu, J.H., Wu, Y.G., Zuo, X.B., Gao, J.P., Lin, Y., Zhu, Z.W., Wen, L.L., Yang, C., Liu, L., Cheng, Y.Y., Chang, Y., Yang, L.L., Zhou, F.S., Tang, X.F., Zheng, X.D., Yin, X.Y., Tang, H.Y., Sun, L.D., Cui, Y., Yang, S. and Zhang, X.J. (2015) Association analyses confirm five susceptibility loci for systemic lupus erythematosus in the Han Chinese population. *Arthritis Res. Ther.*, **17**, 85.
 18. Lessard, C.J., Adrianto, I., Ice, J.A., Wiley, G.B., Kelly, J.A., Glenn, S.B., Adler, A.J., Li, H., Rasmussen, A., Williams, A.H., Ziegler, J., Comeau, M.E., Marion, M., Wakeland, B.E., Liang, C., Ramos, P.S., Grundahl, K.M., Gallant, C.J., Alarcón-Riquelme, M.E., Alarcón, G.S., Anaya, J.M., Bae, S.C., Boackle, S.A., Brown, E.E., Chang, D.M., Cho, S.K., Criswell, L.A., Edberg, J.C., Freedman, B.I., Gilkeson, G.S., Jacob, C.O., James, J.A., Kamen, D.L., Kimberly, R.P., Kim, J.H., Martin, J., Merrill, J.T., Niewold, T.B., Park, S.Y., Petri, M.A., Pons-Estel, B.A., Ramsey-Goldman, R., Reveille, J.D., Scofield, R.H., Song, Y.W., Stevens, A.M., Tsao, B.P., Vila, L.M., Vyse, T.J., Yu, C.Y., Guthridge, J.M., Kaufman, K.M., Harley, J.B., Wakeland, E.K., Langefeld, C.D., Gaffney, P.M., Montgomery, C.G. and Moser, K.L. (2012) Identification of IRF8, TMEM39A, and IKZF3-ZBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. *Am. J. Hum. Genet.*, **90**, 648-660.
 19. Kim, A.Y., Kwak, J.H., Je, N.K., Lee, Y.H. and Jung, Y.S. (2015) Epithelial-mesenchymal transition is associated with acquired resistance to 5-fluorouracil in HT-29 colon cancer cells. *Toxicol. Res.*, **31**, 151-156.
 20. Li, Y., Park, J., Piao, L., Kong, G., Kim, Y., Park, K.A., Zhang, T., Hong, J., Hur, G.M., Seok, J.H., Choi, S.W., Yoo, B.C., Hemmings, B.A., Brazil, D.P., Kim, S.H. and Park, J. (2013) PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. *Cell. Signal.*, **25**, 74-84.
 21. Kim, I.S., Yang, S.Y., Han, J.H., Jung, S.H., Park, H.S. and Myung, C.S. (2015) Differential gene expression in GPR40-overexpressing pancreatic β -cells treated with linoleic acid. *Korean J. Physiol. Pharmacol.*, **19**, 141-149.
 22. Bioinformatics, U.G. (2015) Human Genome Sequencing Consortium. Available from: <http://genome.ucsc.edu/>.
 23. Kim, D. and Salzberg, S. (2015) TopHat 2.1.0 release [cited 2015 Jun 29]. Available from: <https://ccb.jhu.edu/software/tophat/index.shtml/>.
 24. Na, C.H., Hong, J.H., Kim, W.S., Shanta, S.R., Bang, J.Y., Park, D., Kim, H.K. and Kim, K.P. (2015) Identification of protein markers specific for papillary renal cell carcinoma using imaging mass spectrometry. *Mol. Cells*, **38**, 624-629.
 25. Cheon, J.M., Kim, D.I. and Kim, K.S. (2015) Insulin sensitivity improvement of fermented Korean Red Ginseng (Panax ginseng) mediated by insulin resistance hallmarks in old-aged ob/ob mice. *J. Ginseng Res.*, **39**, 331-337.
 26. Zhang, J., Ma, Y., Qiu, M., Yang, L., Bu, Y. and Tang, X. (2014) Correlation between TMEM39A gene polymorphism and systemic lupus erythematosus in Chinese Han patients. *Nan Fang Yi Ke Da Xue Xue Bao*, **34**, 556-559.
 27. Goodman, S.R. (2008) Medical cell biology in *Medical Cell Biology* (Goodman, S.R. Ed.). Academic Press, p. 37.